Article
Multidisciplinary Sciences
Miriam Manook, Danae Olaso, Imran J. Anwar, Janghoon Yoon, Isabel Delaura, Yeeun Bae, Dimitrios Moris, Brian Shaw, Mingqing Song, Alton B. Farris, Annette Jackson, Jean Kwun, Stuart Knechtle
Summary: This study examined the effectiveness of costimulation blockade and proteasome inhibition for desensitization in female NHPs sensitized by pregnancy alone. The results showed that the addition of belatacept and tacrolimus significantly prolonged graft survival and suppressed the production of donor-specific antibodies.
Article
Urology & Nephrology
Karim El Sakhawi, Giovanna Melica, Anne Scemla, Dominique Bertrand, Cyril Garrouste, Paolo Malvezzi, Philippe Remy, Anissa Moktefi, Alexandre Ingels, Cecile Champy, Jean-Daniel Lelievre, David Kheav, Antoine Morel, David Mokrani, Philippe Attias, Philippe Grimbert, Marie Matignon
Summary: The study found that the switch from CNI to belatacept in HIV-positive kidney allograft recipients may increase long-term kidney allograft survival rates. Results showed that the conversion treatment did not increase the risk of HIV replication after a year, but the importance of patient medication compliance and adverse events should be noted.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Urology & Nephrology
Amogh Agrawal, Grace Yun Chong, Mary Elizabeth Fidler, Carl Henry Cramer II, Hatem Amer, Andrew John Bentall
Summary: Post-transplant recurrence of AAV is rare, and recurrence within 2 weeks after transplantation is even rarer. We present a unique case of AAV recurrence 2 weeks post-transplant. The patient received a deceased donor kidney transplant after 6 years on hemodialysis due to AAV. She was initially induced with thymoglobulin and steroids and maintained on belatacept, mycophenolate, and prednisone. A repeat biopsy revealed findings consistent with recurrent AAV, and she was treated with rituximab, prednisone, and intravenous immunoglobulin. Renal function began to recover after treatment.
JOURNAL OF NEPHROLOGY
(2023)
Article
Surgery
Idelberto R. Badell, Ronald F. Parsons, Geeta Karadkhele, Octav Cristea, Sue Mead, Shine Thomas, Jennifer M. Robertson, Grace S. Kim, John J. Hanfelt, Stephen O. Pastan, Christian P. Larsen
Summary: The study showed that belatacept therapy every 2 months is noninferior to monthly therapy in renal transplant patients, with good safety and tolerability. Although some rejection episodes and cases of donor-specific antibodies occurred in the every 2-month treatment group, adherent subjects to the study protocol only experienced a small number of these complications.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Review
Medicine, General & Internal
Yannis Lombardi, Helene Francois
Summary: The current gold standard for preventing allograft rejection in kidney transplantation is the use of glucocorticoids, an antiproliferative agent, and a calcineurin inhibitor. Belatacept, a fusion protein, shows potential benefits for kidney function, but conversion to belatacept may increase the risk of acute rejection and certain infectious diseases.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Thibault Letellier, Delphine Kervella, Abderrahmane Sadek, Christophe Masset, Claire Garandeau, Cynthia Fourgeux, Victor Gourain, Jeremie Poschmann, Gilles Blancho, Simon Ville
Summary: This study analyzed the effects of a time-limited strategy of belatacept therapy/withdrawal of calcineurin inhibitors in kidney transplant recipients. The results showed that eGFR remained stable after belatacept withdrawal, and patients who resumed belatacept had a better eGFR trend. Additionally, the withdrawal of belatacept did not lead to rebound in alloimmune response.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Engineering, Multidisciplinary
Tsuyoshi Takamura, Kenji Matsui, Naoto Matsumoto, Yatsumu Saito, Toshinari Fujimoto, Susumu Tajiri, Shuichiro Yamanaka, Kei Matsumoto, Akimitsu Kobayashi, Izumi Yamamoto, Hiroshi Sasaki, Haruyuki Hirayama, Hitomi Matsunari, Kazuaki Nakano, Hiroshi Nagashima, Akihiko Kiyoshi, Takao Kuroda, Makoto Inoue, Takeshi Miyawaki, Takashi Yokoo, Eiji Kobayashi
Summary: This study compared the transplant rejection between neonatal and fetal pig kidneys in renal heterotransplantation. The results showed that fetal pig kidneys were spared from rejection despite the administration of the same immunosuppressive protocol to the monkeys and the recipient blood vessels flowing into the fetal kidneys.
Article
Surgery
Geeta Karadkhele, Julien Hogan, Wairimu Magua, Weiwen Zhang, Idelberto Raul Badell, Aneesh Mehta, Marshall Lyon, Stephen Pastan, Thomas C. Pearson, Christian P. Larsen
Summary: In CMV high-risk kidney transplant recipients, belatacept-based maintenance immunosuppression may increase the risk of primary CMV infection and prolong the course of viral replication. While patients treated with belatacept showed a trend towards lower graft survival, this conclusion was not statistically significant. Further studies are needed to confirm these findings and explore the relationship between belatacept treatment and CMV outcomes.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Immunology
Ibrahim Tawhari, Patrick Hallak, Sofia Bin, Fatmah Yamani, Maria Safar-Boueri, Aazib Irshad, Joseph Leventhal, Mohammed Javeed Ansari, Paolo Cravedi, Lorenzo Gallon
Summary: This study evaluated the use of Belatacept in kidney transplant recipients and found a higher rate of biopsy-proven acute rejection in the Bela+MPA treatment group, while the Bela+low-dose Tac group showed an increase in eGFR.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Urology & Nephrology
Klemens Budde, Rohini Prashar, Hermann Haller, Maria C. Rial, Nassim Kamar, Avinash Agarwal, Johan W. de Fijter, Lionel Rostaing, Stefan P. Berger, Arjang Djamali, Nicolae Leca, Lisa Allamassey, Sheng Gao, Martin Polinsky, Flavio Vincenti
Summary: This study demonstrates that converting stable renal transplant recipients from CNI-based to belatacept-based maintenance immunosuppression improves renal function and reduces the risk of acute rejection, making it a suitable alternative for patients intolerant to CNIs.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Hyoung-Yun Han, Mi-Sun Choi, Seokjoo Yoon, Je-Won Ko, Sang-Kyum Kim, Tae-Won Kim
Summary: This study confirmed kidney-biased organ toxicity of ifosfamide in rats, with identically altered genes in both the liver and kidney. Interferon regulatory factor 7 was identified as the main upstream regulator that changed in both organs. Further toxicogenomic studies are needed to fully understand the relationship between ifosfamide-induced genes and organ toxicity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Robert P. Carroll, Michael Boyer, Val Gebski, Bronwyn Hockley, Julie K. Johnston, Svjetlana Kireta, Hsiang Tan, Anne Taylor, Kate Wyburn, John RZalcberg
Summary: Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors.
Article
Surgery
Grace Lassiter, Ryo Otsuka, Takayuki Hirose, Ivy Rosales, Ahmad Karadagi, Toshihide Tomosugi, Abbas Dehnadi, Hang Lee, Robert B. Colvin, Jason Baardsnes, Anna Moraitis, Emma E. Smith, Zahida Ali, Phil Berhe, Andrew Mulder, Bernd Meibohm, Bruce Daugherty, Siobhan Fogarty, Richard N. Pierson, Seth Lederman, Tatsuo Kawai
Summary: TNX-1500, a modified anti-CD154 monoclonal antibody, effectively prevents kidney allograft rejection without causing platelet activation, thus avoiding previously identified thrombotic complications associated with this pathway.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Dixon B. Kaufman, E. Steve Woodle, Adele Rike Shields, John Leone, Arthur Matas, Alexander Wiseman, Patricia West-Thielke, Ting Sa, Eileen C. King, Rita R. Alloway
Summary: The study compared the outcomes of kidney transplant patients receiving belatacept versus tacrolimus for maintenance immunosuppression with rapid steroid withdrawal over a period of 2 years. The results showed similar patient and graft survival rates between the groups, but a significantly lower incidence of eGFR <45 ml/min per 1.73 m(2) in the belatacept group and a significantly higher incidence of biopsy-proven acute rejection.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Biochemistry & Molecular Biology
Da-Bin Hwang, Min Ho Cha, Dong-Hoon Won, Yoo-Sub Shin, Shin-Young Kim, Changuk Kim, Eun-Ji Lee, Yoon Young Kim, Jun-Won Yun
Summary: Cisplatin, although an effective platinum-based anticancer drug, has limited availability due to its adverse side effects. This study found that male rats are more susceptible to cisplatin-induced nephrotoxicity, which is associated with renal dysfunction, testicular damage, and an imbalance in male hormone regulation. Additionally, genes related to gap junctions and mismatch repair were enriched in males following cisplatin treatment, shedding light on the potential mechanisms of sex differences in cisplatin-induced nephrotoxicity.
FREE RADICAL BIOLOGY AND MEDICINE
(2021)